Why in news
The U.S. Food and Drug Administration (FDA) recently approved a drug called Cobenfy to treat schizophrenia.
What is Cobenfy ?
Cobenfy is the first antipsychotic drug to treat schizophrenia by targeting cholinergic receptors instead of dopamine receptors.
Cobenfy is a combination of xanomeline and trospium chloride that has a novel mechanism of action that steers clear of older drugs’ side effects, too.
It has side effects of its own, though
What is Schizophrenia?
It is a severe mental disorder, characterized by profound disruptions in thinking, affecting language, perception, and the sense of self.
It affects more than 21 million people worldwide
It typically begins in late adolescence or early adulthood.
Impact: Hallucinations, delusions, reduced speaking, reduced ability to understand information and decision making, trouble in focusing or paying attention etc.
What causes schizophrenia?
Researchers believe that genetic as well as environmental factors such as exposure to viruses contribute to causation, and also life stressors may play a role in the disorder’s onset and course.
Schizophrenia is a treatable disorder.
Therapy and support can help people learn social skills, cope with stress, identify early warning signs of relapse and prolong periods of remission.
COMMENTS